Costa RicaTuberculosis profile
Population  2014 4.8 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.039 (0.037–0.041) 0.83 (0.78–0.87)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.15 (0.11–0.19)
Prevalence  (includes HIV+TB) 0.65 (0.29–1.1) 14 (6.2–24)
Incidence  (includes HIV+TB) 0.53 (0.47–0.6) 11 (9.8–13)
Incidence (HIV+TB only) 0.054 (0.047–0.061) 1.1 (0.99–1.3)
         
Case detection, all forms (%) 87 (77–99)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.5 (0.42–3.8) 4.5 (0.12–23)
MDR-TB cases among notified pulmonary
TB cases
6 (2–15) 1 (0–4)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 380   10
Pulmonary, clinically diagnosed 7   0
Extrapulmonary 63   3
       
Total new and relapse 463    
Previously treated, excluding relapses 6    
Total cases notified 469    
Among 463 new and relapse cases:
26 (6%) cases aged under 15 years; male:female ratio: 1.9
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 1 (5%) 1
Laboratory-confirmed RR-/MDR-TB cases     1
Patients started on MDR-TB treatment ***     1
TB/HIV 2014 Number (%)
TB patients with known HIV status 442 (94)
HIV-positive TB patients 41 (9)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 41 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 41 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (88) 420
Previously treated cases, excluding relapse, registered in 2013 (50) 6
HIV-positive TB cases, all types, registered in 2013 (69) 42
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 2.1
Culture (per 5 million population) 16.8
Drug susceptibility testing (per 5 million population) 1.1
Sites performing Xpert MTB/RIF 4
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-26 Data: www.who.int/tb/data